Table 7.
Levels of cytokines and soluble cytokine receptors in various stages of disease progression.
| Parameter | Patients with MM treated with antiproliferative therapy | p | |||
|---|---|---|---|---|---|
| Without disease progression | With disease progression | ||||
| n | mean ± SD | n | mean ± SD | ||
| IL-6 (pg/ml) | 20 | 4.14 ± 5.75 | 18 | 19.59 ± 58.15 | NS |
| sIL-6R (ng/ml) | 20 | 31.2 ± 9.1 | 18 | 38.4 ± 15.4 | NS |
| VEGF (pg/ml) | 20 | 47.4 ± 33.9 | 18 | 55.2 ± 54.0 | NS |
| sVEGF-R2 (pg/ml) | 20 | 7591 ± 1612 | 18 | 7066 ± 2682 | NS |
| HGF (pg/ml) | 23 | 1283 ± 1583 | 18 | 3555 ± 4498 | <0.001 |
| b-FGF (pg/ml) | 23 | 6.46 ± 9.17 | 18 | 9.71 ± 12.51 | NS |
| TGF-β1 (ng/ml) | 22 | 10.84 ± 6.28 | 18 | 12.33 ± 6.33 | NS |
b-FGF, b-fibroblast growth factor; HGF, hepatocyte growth factor; IL-6, interleukin-6; MM, multiple myeloma; NS, not significant; sIL-6R, soluble IL- 6 receptor; SD, standard deviation; sVEGF-R2, soluble VEGF receptor; TGF-β1, transforming growth factor-β1; VEGF, vascular endothelial growth factor.